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Treatment outcomes in culture-positive pulmonary tuberculosis
Abstract
Introduction: The aim of the study was to evaluate treatment outcomes in sputum culture positive patients with tuberculo-
sis in three Polish provinces (Warsaw, Gdansk and Siedlce Provinces) in 1995 and again in 2000. We also assessed whether
the implementation of the Directly Observed Therapy Short Course (DOTS) strategy in the former Gdansk Province led to
improved outcomes compared to the outcomes observed in 1995, when this strategy was not being followed.
Material and methods: We started the study by reviewing microbiology registers covering the years 1995 and 2000 from
all the tuberculosis laboratories in three provinces (Warsaw, Gdansk and Siedlce Provinces) and identified sputum culture
positive patients. We then reviewed inpatient and outpatient medical records of patients who had been with pulmonary
tuberculosis diagnosed and confirmed by bacteriology in 1995 and 2000. Treatment outcomes were evaluated in accor-
dance with the World Health Organisation (WHO) recommendations and classified as: cure, treatment completed, default,
treatment failure, death or other.
Results: A total of 708 patients were included in the study: 373 diagnosed in 1995 and 335 diagnosed in 2000. According to
the WHO criteria, the treatment success rate (the sum of cures and treatment completions) in 1995 and 2000 was 58.8%
and 54.0%, the default rate was 15.5% and 17.9%, the failure rate was 2.4% and 2.7% and the death rate was 5.6% and 6.3%,
respectively. The rate of outcomes classified as “other” was 18.2% and 22.1%, respectively. Following the implementation of
the DOTS strategy in Gdansk Province, treatment outcomes in significantly improved in 2000 compared to the year 1995.
The treatment success rate was 89.6% vs 69.3% (p = 0.0037), the default rate was 0.0% vs 14.7% (p = 0.0005) and the
death rate was 0.0% vs 9.3%  (p = 0.0184).
Conclusions: The treatment success rate (the rate of cures and treatment completers) in 1995 and 2000 was 58.8% and
54.0% and was lower than that recommended by WHO (at least 85%). The results demonstrated that the treatment
outcomes in the former Gdansk Province in 2000, following the implementation of the DOTS strategy, were significantly
better than those in 1995, when the strategy was not being followed. Treatment success was observed in 89.6% and 69.3%
of the patients, respectively (p = 0.0037).
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Introduction
According to the World Health Organisation
(WHO) experts, a tuberculosis control system is ef-
fective if it ensures that at least 70% sputum smear
patients are detected and at least 85% of newly
detected patients with microbiologically confirmed
presence of mycobacteria in the sputum are cured [1].
Modern treatment of tuberculosis allows to achie-
ve treatment success rates of more than 95% and
to reduce the failure rate to 5% [2].
Given the unfavourable epidemiological situ-
ation of tuberculosis in the poorest countries and
the increasing prevalence rates in the developing
countries, WHO classified tuberculosis in 1993 as
a global risk [3]. A year later, in collaboration with
other international organisations involved in tuber-
culosis control, WHO announced a new strategy
for the monitoring and treatment of patients with
tuberculosis, the DOTS (Directly Observed Treat-
ment, Short Course) strategy [4, 5]. It is a compre-
hensive strategy aimed to detect, treat and cure
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Material and methods
The study was conducted on the territory of
three Polish provinces (according to the admini-
strative division of Poland as at 1995): Warsaw,
Gdansk and Siedlce provinces.
We started the study by reviewing microbio-
logy registers covering the years 1995 and 2000
from all the tuberculosis laboratories in each of the
three provinces and identifying patients with po-
sitive sputum cultures for Mycobacterium tubercu-
losis.
Demographic data contained in the laborato-
ry request forms made it possible to trace the
healthcare facility that had sent the specimens for
bacteriology.
In order to establish whether the patient who
had been registered at the tuberculosis laboratory
providing bacteriological confirmation of tubercu-
losis based on the positive sputum culture started
antituberculosis treatment, we reviewed the pa-
tient’s medical records at the healthcare facility
which had provided specimens for bacteriology.
The following patients were excluded from the
study: patients entitled to receive medical care
under special schemes (Ministry of National De-
fence, Ministry of Internal Affairs and the Polish
Railways), patients with bacteriologically confir-
med pulmonary tuberculosis in a year preceding
the years of interest in our study (i.e. in 1994 and
1999), patients living outside the territories of in-
terest in our study (as the laboratories based in the
three provinces we investigated also performed
bacteriology testing for other provinces), patients
who continued treatment outside the three provin-
ces investigated following the initial phase of the-
rapy and patients who had been registered at
a healthcare facility (inpatient or outpatient) but
whose medical records could not be found for va-
rious reason.
We then analysed inpatient and outpatient
treatment records for patients diagnosed with pul-
monary tuberculosis confirmed by bacteriology in
1995 and 2000 who did not meet the exclusion
criteria.
A total of 708 patients were included in the
study: 373 patients diagnosed with tuberculosis in
1995 and 333 diagnosed in 2000. We verified whe-
ther all the included patients had received antitu-
berculosis treatment. Patients were considered
untreated if:
— no records were found, despite every effort, to
demonstrate that the patient had been registe-
red at the healthcare facility from which the
specimen for bacteriology was sent and the no
patients with tuberculosis covered by healthcare
schemes and should be at the core of tuberculosis
control programmes in each country. This is con-
firmed by experiences of many countries, as the
strategy has been demonstrated to result in very
good treatment outcomes as well as being cost ef-
fective [6–10].
Patient adherence to treatment is an important
problem affecting treatment outcomes. According
to studies evaluating antituberculosis treatment
outcomes, only directly observed treatment (DOT),
which involves taking the drugs by the patient in
the presence of a healthcare professional, such as
a doctor, nurse or another specially trained person,
ensures optimal treatment outcomes [6, 7, 11, 12].
Thanks to the inclusion of DOT in tuberculosis
control programmes, a reduction in the incidence
of tuberculosis has been observed in many coun-
tries [13].
WHO, in collaboration with other internatio-
nal organisations involved in tuberculosis control,
has developed precise definitions of tuberculosis
cases and treatment outcomes. These definitions
are aimed to enable the correct recording, classifi-
cation and counting of individual tuberculosis ca-
ses, to assess the percentage of new cases with spu-
tum positivity and the percentage of recurrences
among all the patients with pulmonary tuberculo-
sis, and to determine the appropriate combination
of antituberculosis drugs for an individual patient
[5]. Appropriate systems for data collection are also
provided by cohort analyses, which allow treat-
ment outcomes to be evaluated in all the patients
diagnosed with tuberculosis over a given period of
time.
In Poland, thanks to the implementation of the
tuberculosis control programme and the widespre-
ad adoption of the WHO treatment standards, the
recent years have seen a consistent reduction in
the incidence of tuberculosis. WHO monitors the
implementation of DOTS in individual countries
and in 1999 Poland was assigned category 3 and
was one of the twelve countries to have subsequen-
tly improved its category.
According to WHO, cohort analyses are the
best method of assessing the efficiency of tuber-
culosis control systems, which is why the aim of
our study was to evaluate treatment outcomes in
all patients with pulmonary tuberculosis confir-
med by positive sputum cultures on the territory
of three Polish provinces in 1995 and again in 2000.
We also investigated whether the implementation
of the DOTS strategy in the former Gdansk Provin-
ce improved outcomes in 2002 versus 1995, when
the strategy was not yet being followed.
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further bacteriology testing reports were ava-
ilable at the laboratory to show that the patient
was being followed up;
— the medical records we found revealed no in-
formation about the commencement of antitu-
berculosis treatment (for patients discharged
home in whom no tuberculosis had been dia-
gnosed we verified whether they were registe-
red at their local pulmonary outpatient clinic or
another outpatient clinic in the town they lived);
— they received antituberculosis drugs for less
than a month (untreated patients according to
the WHO definition) [1, 14].
We verified how many patients had started
antituberculosis treatment, who were defined as
patients who had received antituberculosis drugs
for at least one day.
The selection of drugs and the duration of
treatment were reviewed for compliance with the
WHO guidelines [1, 14]. We considered the follo-
wing combinations of drugs to be model treatment
regimens:
— RMP+INH+PZA+EMB/SM for 2 months (ini-
tial phase) and RMP+INH for 4 months (con-
tinuation phase), or
— RMP+INH+PZA for 2 months (initial phase)
and RMP+INH for 4 months (continuation
phase);
— RMP+INH+EMB/SM for 3 months (initial
phase) and RMP+IHN for 6 months (continu-
ation phase).
If a patient had not received any of the model
regimens, he/she was included in the group recei-
ving another combination.
The durations of treatment with the individu-
al antituberculosis drugs were calculated from the
start and end of treatment dates. In the evaluation
of the correctness of using individual combinations
of drugs we accepted the possibility of extending
or shortening of treatment phases by less than 10%.
All the other cases were classified as “excessive”
or “insufficient” duration of treatment.
If a patient had interrupted treatment and the
interruptions were less than 2 months long and
then continued treatment in accordance with the
same regimen, then in line with the WHO guideli-
nes [1] the treatment was considered as one cour-
se and the periods of drug intake were combined.
We also evaluated the percentage of patients
with culture negativisation during the treatment
period.
We evaluated the time to culture negativisa-
tion by counting the number of days between the
start of treatment and the first negative sputum
culture. It was impossible to evaluate the culture
negativisation rate, as the cohort did not undergo
regular bacteriology testing. Whether the treatment
was systematic was evaluated on the basis of in-
terruptions in drug intake. A “short interruption”
was defined as an interruption in drug intake by
the patient of less than 2 months. The cause of in-
terruption was evaluated. The reasons for interrup-
ting treatment were investigated, paying special
attention to cases when the patient gave up treat-
ment right after discharge from hospital.
Treatment outcomes were evaluated in accor-
dance with the relevant WHO guidelines and pa-
tients were categorised as follows [1]:
— Cure: Patient who had completed full antitu-
berculosis treatment and was culture negati-
ve at the end of the treatment.
— Treatment completed: Patient who had com-
pleted the assigned treatment but final sputum
cultures were not obtained and the supervi-
sing doctor decided that the patient required
no further treatment.
— Default: Patient who had taken antituberculo-
sis drugs for one or more months and inter-
rupted treatment for two or more months.
— Treatment failure: Patient in whom sputum
culture remained or became positive at 5 months
of antituberculosis treatment.
— Death: Patient who died for any reason during
antituberculosis treatment.
— Other: Patient who does not meet the criteria
to be classified as any of the above category.
This group includes: patients who had not un-
dergone antituberculosis treatment (i.e. patients
who had not received any treatment at all and
patients who had been treated for less than one
month) and patients whom their doctor consi-
dered cured and terminated treatment but the
duration of treatment was “insufficient”.
Treatment success was defined as the sum of
patients whose outcome was categorised as “cured”
and “treatment completed”.
If a patient interrupted treatment for more than
two months and resumed treatment after the in-
terruption, the outcome of retreatment was asses-
sed. If multi-drug resistance to antituberculosis
drugs was the cause of treatment failure, the group
of these patients was excluded from further ana-
lysis.
Statistical analysis
The differences between related variables were
analysed with the non-parametric Wilcoxon test.
The test compares the sum of positive difference
ranks with that of negative difference ranks. The
differences in the frequencies of patients with the
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trait of interest were analysed with the chi-square
test (observed vs expected values). For binominal
frequency tables (2 by 2) the chi-square test, v-squ-
are test, chi-square test with Yates correction or the
Fisher test, as recommended by the relevant lite-
rature [15], were used. We assumed that the rela-
tionships or differences we were investigating
would be statistically significant if the p value was
less than 0.05.
Results
We evaluated medical records of 708 patients
including 373 patients diagnosed in 1995 and 335
diagnosed in 2000. Positive smears were present in
157 (42.1%) and 119 (35.5%) patients, respective-
ly. The proportion of smear-positive patients in 2000
was lower than that in 1995, although the differen-
ce was not statistically significant (p < 0.0869).
Management of patients in the study groups
In 1995 forty-three (11.5%) patients did not
start treatment. Antituberculosis treatment was
initiated in 330 (88.5%) patients but its duration
was less than a month in 15 (4.5%) patients. In
2000 treatment was not initiated in 45 (13.4%)
patients. The remaining 290 (86.6%) patients star-
ted treatment but in 8 (2.4%) patients its duration
was less than a month (Fig. 1).
Sputum culture negativisation
In 1995 two hundred and seventy-nine
(74.8%) patients achieved sputum culture negati-
visation, while 94 (25.2%) did not. The latter in-
cluded 43 untreated patients, 25 defaults, 9 treat-
ment failures and 13 patients who died in the co-
urse of treatment. In 2000 two hundred and sixty
(77.6%) patients achieved sputum culture negati-
visation while, while 75 (22.4%) did not. The la-
tter included 45 untreated patients, 11 defaults,
7 failures and 7 deaths.
Furthermore, 4 patients in 1995 and 2 in 2000
completed the correctly conducted therapy but
because in the course of the treatment they had stop-
ped expectorating, they could not undergo follow-
-up bacteriology and obtain a definite confirmation
of sputum culture negativisation. Due to the lack of
evidence for sputum culture negativisation these
patients were included in this group. These patients
had initially been sputum smear-negative.
No statistically significant difference was fo-
und between the years 1995 and 2000 in the num-
ber of patients achieving negativisation and the
number of patients not achieving negativisation
during the treatment (p = 0.4877).
By the end of 3 months of treatment negativisa-
tion was achieved in 235 (63%) patients in 1995 and
in 217 (64.8%) in 2000. By the end of 5 months of
treatment negative cultures were reported for further
32 (8.6%) and 26 (7.8%) patients, respectively.
Sputum culture negativisation was achieved
in 12 (3.2%) patients in 1995 within 6–11 months
and in 17 (5.1%) patients in 2000 within 6–24 months.
This group included patients who had defaulted
but subsequently resumed treatment to continue
it and patients who did not undergo regular spu-
tum bacteriology (Fig. 2).
Figure 1. A history of patients in the study groups
Figure 2. The time to conversion of positive sputum cultures in the
study groups
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Regularity of treatment
Treatment was interrupted for less than
2 months by 40 out of 330 patients (12.1%) in 1995
and 9 out of 290 patients (3.1%) in 2000.
In 1995 brief interruptions of treatment were
caused by adverse reactions in 16 patients and by
incompliance in the remaining cases. The respecti-
ve numbers in 2000 were 3 and 6 (Table 1). No sta-
tistically significant difference was found between
the years 1995 and 2000 in the causes of brief inter-
ruptions of treatment (p < 0.2059, p < 0.3137).
Treatment outcomes
Cure, as defined by WHO [10], was achieved
in 48.8% and 40.9% of the patients in 1995 and
2000, respectively. Treatment was completed by
11.0% and 13.1%, respectively. Treatment success
was observed in 59.8% (223/373) and 54.0% (181/
/335) of the patients, respectively. In 1995 a total
of 15.5% of the patients (58/373) defaulted: 54 due
to incompliance and 4 due to poor treatment tole-
rability. At discharge from hospital 26 patients
defaulted. After the treatment interruption 12 pa-
tients were re-treated, 5 of whom (41.6%) were cu-
red and 7 defaulted again. In 2000 a total of 17.9%
(60/335) of the patients defaulted: 53 due to incom-
pliance and 7 due to poor treatment tolerability. At
discharge from hospital 39 patients defaulted, 7 of
whom were re-treated, 4 of whom (57.1%) were
cured. Three patients defaulted again.
Treatment failure was observed in 2.4% (9/373)
of the patients in 1995. Four patients were resi-
stant to rifampin (RMP) and isoniazid (INH).
Of the 5 patients with cultures positive for myco-
bacteria sensitive to the basic antituberculosis
drug, sputum culture negativisation following re-
treatment was achieved in 2 patients, who subse-
quently defaulted. Sputum culture negativisation
could not be achieved in 3 patients.
In 2000, treatment failure was reported in 2.7%
(9/335) of the patients. Six patients were found to
be resistant to RMP and INH. Three drug sensitive
patients were cured following re-treatment.
Four percent (15/373) and 3.3% (11/335) of the
patients died in the course of treatment in 1995 and
2000, respectively, with tuberculosis being the
cause of death in 3.2% (12/373) and 2.4% (8/335)
of the cases, respectively.
Treatment outcome was classified as “other” in
18.2% of the patients in 1995. The group comprised
49 untreated patients (including 6 patients who had
received treatment for less than a month) and
19 patients who had been considered cured by their tre-
ating physicians and completed treatment as plan-
ned but the actual duration of treatment according
to the regimen used was shorter than recommended.
In 2000 the “other” treatment outcome group
comprised 22.1% of the patients, including 50 untre-
ated patients (5 of whom had received treatment for
less than a month) and 24 patients considered cu-
red but whose duration of treatment was regarded
as “insufficient”. No statistically significant diffe-
rences were observed in the treatment outcomes
between the years 1995 and 2000 (Table 2).
In 1995 treatment success was reported in
52 patients (69.3%), default in 11 patients (14.7%),
failure in 3 patients (4.0%) and death in 7 patients
(9.3%) with all the fatal cases being due to tuber-
culosis. Two patients (2.7%) had not started anti-
tuberculosis treatment (with one patient dying
before treatment was initiated).
In 2000 treatment success was observed in
69 patients (89.6%). There was one failure (1.3%) and
no defaults or deaths in the course of treatment.
Six patients considered cured by the doctor super-
vising the treatment had in fact been treated too
briefly and one had not been treated at all (the
patient had died from tuberculosis before treatment
was initiated) (Table 3). The treatment success rate
in 2000 was significantly higher than that in 1995
(p = 0.0037). The default and death rates in 2000
were significantly lower than those in 1995 (p =
0.0005 and p = 0.0184, respectively).
In 1995 the treatment success rate was 57.4%,
default rate was 15.8%, failure rate was 2.0% and
the death rate was 2.7%. Treatment outcomes were
classified as “other” in 22.1% of the patients.
In 2000 the success rate was 43.4% and the de-
fault rate was 23.3%. The failure and death rates were
3.1% and 4.3%, respectively, and in 25.6% of the
Table 1. Reasons of the short interruptions of the treatment in the study groups
Reason for short                                     1995                                          2000
 interruption of treatment Number of patients Percent of patients Number of patients Percent of patients
Bad compliance 24 60,0 6 66,7
Side effects 16 40,0 3 33,3
Total 40 100,0 9 100,0
Pneumonologia i Alergologia Polska 2009, vol. 77, no 1, pages 11–22
16 www.pneumonologia.viamedica.pl
patients treatment outcomes were categorised as
“other” (Table 4). The treatment success rate in 2000
was significantly higher than that in 1995 (p = 0.005).
Long-term observations
Our review of the medical records demonstra-
ted 2 relapses and 11 deaths in the 242 patients dia-
gnosed in 1995 who completed treatment and were
considered cured by their doctors. Both relapses oc-
curred a year and a half after completion of treatment
and all the deaths were unrelated to tuberculosis.
In the group of patients diagnosed in 2000 and
considered cured following completion of treat-
ment, there were 2 relapses (one year and a year
and a half after completion of treatment) and
3 deaths (all unrelated to tuberculosis) (Table 5).
Discussion
Successful antituberculosis treatment and
the continuous reduction in the incidence of tu-
berculosis are determined by the percentage of
patients completing therapy and achieving treat-
ment success, which should not be lower than
85%, according to the WHO guidelines [1, 14].
This group of patients comprises cured patients
with negative sputum culture at the end of treat-
ment and patients who have completed treatment
as planned but have not undergone sputum
bacteriology at the end of treatment for various re-
asons. Therefore, the percentage of defaults, deaths
and treatment failures cannot exceed 15%
in total [1, 16].
We demonstrated that the success rate in 1995
and 2000 (the combined rate of cured and treat-
ment completed) was much higher than that re-
commended by WHO (Table 2).
During treatment sputum culture negativisa-
tion was achieved in 74.8% and 77.69% of the pa-
tients in 1995 and 2000, respectively (Fig. 2). The
main reason for the disproportions between the
percentage of patients with negative sputum cul-
Table 2. Treatment outcome in the study groups
                                   1995                                  2000
Results Number of patients Percent of patients Number of patients Percent of patients p-value
Cured 182 48,8 137 40,9
p = 0,1419
Treatment completed 41 11 44 13,1
Defaulted 58 15,5 60 17,9 p = 0,4589
Treatment failure 9 2,4 9 2,7 p = 0,9935
Death 15 4,0 11 3,3 p = 0,7482
— death of tuberculosis 13 3,5 8 2,4 p = 0,5239
— other causes of death* 68 18,2 74 22,1 p = 0,2355
Total 373 100,0 335 100,0
*1995 — 43 untreated patients + 6 patients treated shorter then one month + 19 patients treated too short
*2000 — 45 untreated patients + 5 patients treated shorter then one month + 24 patients treated too short
Table 3. Treatment outcome in 1995 and 2000 in Gdansk area
1995 2000
Results Number of patients Percent of patients Number of patients Percent of patients p-value
Cured 42 56,0 58 75,3
p = 0,0037
Treatment completed 10 13,3 11 14,3
Defaulted 11 14,7 0 0,0 p = 0,0005
Treatment failure 3 4,0 1 1,3 p = 0,5937
Death 7 9,3 0 0,0 p = 0,0184
— death of tuberculosis 7 9,3 0 0,0 p = 0,0184
— other causes of death* 2 2,7 7 9,1 p = 0,9589
Total 75 100,0 77 100,0
*1995 — 2 untreated patients
*2000 — 1 untreated patient + 6 patients treated too short
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Table 4. Treatment outcome in 1995 and 2000 in Warsaw and Siedlce area
1995 2000
Results Number of patients Percent of patients Number of patients Percent of patients p-value
Cured 140 47,0 79 30,6
p = 0,0050
Treatment completed 31 10,4 33 12,8
Defaulted 47 15,8 60 23,3 p = 0,2054
Treatment failure 6 2,0 8 3,1 p = 0,5930
Death 8 2,7 11 4,3 p = 0,4561
— death of tuberculosis 6 2,0 8 3,1 p = 0,5930
— other causes of death* 66 22,1 67 25,6 p = 0,9021
Total 298 100,0 258 100,0
*1995 — 41 untreated patients + 6 patients treated shorter then one month + 19 patients treated too short
*2000 — 44 untreated patients + 5 patients treated shorter then one month + 18 patients treated too short
Table 5. A three-year follow up history of the patients who had a positive treatment outcome in years 1995 and 2000
1995 2000
Follow up history Number of patients Percent of patients Number of patients Percent of patients
Relapse of tuberculosis 2 0,8 2 1,0
Death 11 2,9 3 0,9
Total 242 100,0 205 100,0
ture in the course of treatment and the percentage
of patients achieving permanent sputum culture
negativity was the high percentage of patients de-
faulting after initial negativisation of sputum cul-
tures. Sputum culture negativisation in the initial
phase of treatment, when the patient is usually ho-
spitalised and is taking medication under super-
vision, does not mean cure. Only a correct course
of therapy without treatment interruptions guaran-
tees treatment success and minimises the risk of
relapse [1].
Our study revealed that 11.5% and 13.4% in
1995 and 2000, respectively, did not start antitu-
berculosis treatment in spite of the bacteriological
confirmation of tuberculosis (Fig. 1). These com-
prised patients unregistered at pulmonary clinics
in whom no evidence of receiving antituberculo-
sis treatment was found or who died before treat-
ment was initiated [17].
The management of tuberculosis is a long-
-term process which requires concurrent admini-
stration of multiple drugs, which may cause many
side effects. Tuberculosis management is there-
fore not only a pharmacological issue but also
a psychological and social problem. It is difficult
to persuade a patient who is not experiencing any
symptoms into taking antituberculosis drugs.
Good patient-doctor rapport, persuading the pa-
tient to undergo treatment and motivating him/
/her to continue treatment may contribute to im-
proved outcomes [18–20].
The default rates in 1995 and 2000 were simi-
lar (15.5% vs 17.9%) (Table 2). Nearly 50% of the
patients who defaulted in 1995 did so at dischar-
ge. In 2000 the percentage of these patients was
even higher and equalled 65%. According to lite-
rature, patients most commonly interrupt treat-
ment after being discharged from hospital [21].
In Poland, in line with the applicable legal
regulations adopted years ago (Act of 22 April 1959
on tuberculosis control and, more recently, Act of
6 September 2001 on infectious diseases and in-
fections), there is an obligation of registering tu-
berculosis cases [22, 23]. Any doctor, irrespective
of specialty, who makes a diagnosis of tuberculo-
sis is obliged to report the case in line with the
applicable procedure. Our study has shown that
this obligation is not always complied with. If
a patient starts antituberculosis treatment in a ho-
spital and is subsequently discharged for further
treatment in the outpatient setting, the discharging
doctor should sent the current treatment documen-
tation to the outpatient clinic in which the patient
intends to continue treatment.  If the clinic is no-
tified of the case of tuberculosis, it is possible for
it to undertake actions to persuade the patient who
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fails to show up into continuing therapy. Efficient
flow of information between hospitals and outpa-
tient clinics would make it possible to reduce the
number of patients who default after completion
of hospitalisation.
Many authors confirm that treatment success
may only be ensured by observed therapy [6, 7, 24–
–27]. Directly observed treatment cannot be limited
to the mere observation of patients while they are
swallowing their medication. The DOTS empha-
sises the important role of patient-doctor coopera-
tion viewing it as a partner relation in which the
doctor is responsible for persuading the patient to
undergo treatment, dispelling any concerns and
drawing the patient’s attention to the risks asso-
ciated with interruption of therapy [18].
According to Salomon et al. [28], implemen-
tation of an antituberculosis treatment programme
based on DOT as early as during hospitalisation with
concurrent training on the justifiability of treatment,
health benefits and risks resulting from giving up
the treatment made patients accept the necessity
to undergo observed treatment after discharge from
hospital and continue treatment in the outpatient
setting, thanks to which most of these patients
completed therapy as planned.
Tsuchida et al. [25] demonstrated that follo-
wing the principles of observed treatment by com-
munity nurses increased treatment success rates
compared to patients who were taking their medi-
cation unsupervised (68.3% vs 87.2%).
We found that both in 1995 and 2000, when
patients defaulted in the continuation phase, alre-
ady on the outpatient setting, records of several
patients only demonstrated entries confirming at-
tempts to make contact with the patients to remind
them of the necessity to continue treatment. Most
commonly, however, as indicated by the medical
records, no actions were undertaken to persuade
patients into continuing treatment.
Twelve patients in 1995 and 7 in 2000 were re-
treated, but treatment success was noted only in half
of these patients. The remaining patients subsequ-
ently defaulted again. According to a study conduc-
ted in Istanbul, Turkey, treatment success was achie-
ved in 85% of patients who had been re-treated [29].
For public health, treatment default is more
dangerous than tuberculosis-related deaths becau-
se incomplete treatment, while protecting the pa-
tient from death, leads to increased number of in-
dividuals who are sources of infection. Patients
whose treatment is erratic are infectious for longer
periods and more frequently develop resistance to
basic antituberculosis drugs, which requires using
second-line drugs and prolonged treatment [4].
Poor tolerability of antituberculosis drugs may
be another reason for treatment default [30]. In our
study, however, this was the case in isolated patients.
The number of defaults due to adverse reactions was
16 in 1995 and 3 in 2000 (Table 1). Medical records
did not allow us to establish the causes of early dis-
continuation of drugs. The majority of patients had
experienced unspecified side effects without objec-
tive confirmation in laboratory tests, which might
suggest too hasty decisions to discontinue essential
antituberculous drugs.
The treatment failure rate was 2.4% in 1995
and 2.7% in 2000 (Table 2). Treatment failures
comprised patients with multi-drug resistance and
patients taking their medication irregularly.
Tuberculosis-related deaths occurred in pa-
tients who had not started treatment and in patients
undergoing treatment. Tuberculosis-related deaths
in patients undergoing treatment were more fre-
quent in the first days of therapy, which means that
their condition on admission had been very grave
and they received treatment too late.
The “other” treatment outcome category inclu-
ded patients who did not fit any other outcome
category defined by WHO. These were untreated
patients and patients who had received treatment
for insufficient time from their doctors [31]. The
rates of “other” outcome were 18.2% and 22.1% in
1995 and 2000, respectively (Table 2). Similar ra-
tes have been reported by Sevim et al. [32] and
Lillebaek et al. [33].
According to observations made in many co-
untries, only directly observed therapy is capable
of improving treatment outcomes [7, 11, 13, 27].
The effectiveness of the DOTS strategy is also
confirmed by our own studies. When we compa-
red treatment outcomes in the former Gdansk Pro-
vince, where DOT was followed in 2000, we found
a significant improvement compared to the year
1995, when DOT had not yet been implemented
in the outpatient setting. Of note is the fact that in
2000 none of the patients defaulted compared with
the default rate of 15% in 1995 (Table 3).
When we compared the treatment outcomes
in 1995 and 2000 in Warsaw and Siedlce Provin-
ces, where DOTS was not followed, we found
a significant reduction in the success rate in 2000
versus 1995 and no significant differences betwe-
en 1995 and 2000 in the treatment failure rate or
the default rate (Table 4).
A smoothly functioning healthcare system
supported by appropriate funding results in me-
asureable effects, as evidenced by treatment out-
comes achieved in New York, where the budget for
tuberculosis control increased from 4 to 40 million
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dollars between 1988 and 1994 and DOTS was
implemented on a large scale. By the end of 1994
such treatment had been received by 1200 patients
compared to the mere 50 patients in 1983. In or-
der to make sure that patients were taking their
medication as prescribed, social workers visited
them at home and at work, and visited shelters,
deserted houses, parks and underground stations
in search for homeless people. In 1991 the Depart-
ment of Health recommended using regimens of at
least four antituberculosis drugs (INH, RMP, py-
razinamide [PZA] and ethambutol [EMB]) in all the
patients, which, on the one hand, enabled a more
rapid negativisation paralleled by a shortened dura-
tion of treatment and, on the other, minimised the
risk of treatment failure when drug resistance deve-
loped [2]. Already in the first two years a 21-percent
reduction in new cases of tuberculosis was observed,
and the treatment success rate rose from less than
50% in 1985 to more than 90% in 1994 [34].
Experience from Baltimore, USA, shows that
DOT provided to all patients is superior to DOT
provided to risk groups only [6].
In China and Cuba, treatment success rates of
90% were achieved following the implementation
of DOTS [7].
If the combat against tuberculosis is to be ef-
fective, tuberculosis control programmes must be
in place [35, 36]. If the system is not efficient, even
rich countries do not meet the treatment targets
required by WHO [37]. In Poland, according to the
Central Tuberculosis Register, relapses have
accounted for about 10% of tuberculosis cases for
many years now [38]. According to the literature,
tuberculosis most commonly relapses in the first
two years after completion of treatment [33].
In the group of patients with pulmonary tu-
berculosis diagnosed in 1995 who achieved treat-
ment success the disease relapsed in 2 cases wi-
thin 3 years of treatment completion. Both patients
relapsed 1.5 years after treatment completion. In
the group of patients with pulmonary tuberculo-
sis diagnosed in 2000 who completed treatment as
planned, 4 patients were re-treated. Only 2 cases
were relapses confirmed by bacteriology, and thus
met the WHO criteria for relapse [1, 14]. One re-
lapse was detected after a year and the other after
1.5 years after completion of treatment (Table 5).
The data presented demonstrate that the re-
lapse rate among patients completing the prescri-
bed therapy was low and equalled 0.8% and 1.0%
(Table 5). Similar outcomes in compliant patients
are also achieved in other countries [33, 37, 39].
Relapse rates in incompliant patients are higher
[39]. In Switzerland, in the group of incompliant
patients, the relapse rate at 3 years after treatment
completion was 21% [37].
The number of deaths among treatment com-
pleters diagnosed in 1995 and 2000 was 11 (2.9%)
and 3 (0.9%), respectively, but none of the deaths
was related to tuberculosis (Table 5).
We demonstrated that the treatment outcomes
in the investigated Polish provinces were worse
than those reported to the Central Tuberculosis
Register at the Institute of Tuberculosis and Lung
Diseases in Warsaw, Poland [40]. The percentages
of patients with treatment success in 1995 and
2000 alike were lower than those recommended by
WHO, which largely results from the large num-
ber of untreated patients and defaults. In most ca-
ses, patients defaulted right after being discharged
from hospital and being referred to outpatient cli-
nics for further treatment.
The directly observed treatment recommended
by WHO, used in outpatients, is aimed to prevent
treatment defaults and to improve treatment effica-
cy. In 1995 directly observed treatment was being
provided only to inpatients. During the data collec-
tion outside the investigated regions (Podlaskie and
Gdansk Provinces) DOT was not generally being used
in outpatients. The improved efficacy of treatment
thanks to the implementation of DOTS is evidenced
by the 2000 year outcomes in the former Gdansk Pro-
vince, which were significantly better than those in
1995, before the implementation of this strategy.
Conclusions
1. The percentage of patients with permanently
negative sputum culture in the cohort in
whom treatment success was achieved (cured
and treatment completed) was 58.8% and
54.0% in 1995 and 2000, respectively, and was
lower than the percentage recommended by
WHO (at least 85%).
2. The treatment outcomes in the Mazowieckie
and Siedleckie Provinces in 2000 were signi-
ficantly worse than those in 1995 and the out-
comes achieved in the former Gdansk Provin-
ce in 2000, after the DOTS strategy had been
implemented, were significantly better than
those in 1995, which supports the effective-
ness of the strategy.
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